Why the NIH Should Spend Billions to Give Me Futuristic Real Fake Tits

and How That Would Fast-Track Synthetic Organ Development, Extend Longevity, Solve the Fertility Crisis, and Save Civilization

Ok, I’ve been doing my research. Basically we need the world’s best scientists in regenerative medicine, biomaterials, stem cell biology, voodoo, and synthetic immunology to stop everything they’re doing for 1-5 years to develop a scalable platform for personalized, non-immunogenic fat substitutes aka synthetic fat that integrates seamlessly with the body, to be injected into your tits, creating a new generation of breast implants that actually look real. It will cost millions of dollars per person. But true beauty is not a welfare program. This isn’t Botox at a strip mall. This isn’t Kylie Jenner playing Frankenstein with a Groupon. This is Olympus.

I’m aware that you can currently use your own fat and have it transferred anywhere without this elaborate process. But that requires one to get fat in order to harvest it, and that simply will not do.

Imagine a world where breast implants move naturally with the real motion of the human body—unlike current implants, which are designed to look good in 2D but fail in the third dimension of real life, designed for the kind of man who would rather fuck a jpeg and the symbolic approximation of the thing he wants, rather than of going after real thing. But I am no such man. I am the last man in America who knows what beauty even is. Not aesthetic compliance. Not brand-safe gender conformity. Beauty.

I’ve been trying to convince my scientist friends to abandon their world changing research and dedicate the prime of their careers to this and only this for 1-5 years, but nobody wants to hear it. Least of all the women in STEM, who I naively assumed might understand where I’m coming from. They profoundly don’t. They hesitate because their careers are built on the soft fascism of incrementalism. They shattered the glass ceiling only to become the new gestapo of aesthetic sterility, enforcing beautylessness in the name of consensus. They want “transformative breakthroughs” that don’t offend their tenure review committees. They want Nobel Prizes without the horror of ambition. They want compression underpants. They don’t want to be gods. They want to be middle managers of the sublime. And for that, they will be forgotten.

What I am proposing is a planetary shift in biotechnological ambition: we need an all hands on deck public private Manhattan-project-meets-playboy-in-outer-space research initiative with fast-tracked development, compressed regulatory pathways, and robust legal and ethical oversight, including navigating clinical trials with unprecedented urgency, and creating an entirely new legal framework to support synthetic organ generation.

Right now, we’re focusing on tits. My tits, specifically. But synthetic fat is just the gateway drug. From there, we enter the era of:

-immune-evasive biomaterials

-automated 3D bioprinting systems so like an assembly line for printing liver scaffolding on demand

-tissue blueprint patents $

-AI-guided tissue formation, so organs that self-organize based on what you need

-we could even add extra sensory neurons to breast tissue. We could make your titties bioluminescent. We could do anything.

A manhattan project for synthetic organs is necessary because transplants are dead end at scale. Imagine treating organs like replaceable, programmable modules. This could extend life to like 120 years, not as a ceiling, but as a functional baseline.

If you’re reading this and hoping to live to 200, but you’re not treating your body the way an Olympic athlete treats theirs, then at some point, you’re going to need a new organ. I guarantee that some of you reading this have your shoulders hunched, your neck craned forward, and your jaw clenched. And those small postural habits, repeated daily over years, are quietly destroying your body. You’re going to need new parts if you want to make it to the singularity.

And unless we launch a Manhattan Project–level initiative for synthetic organs, we’re looking at a 15-30 year timeline before we have something like scalable synthetic organs.

People love to say, “AI will solve everything, so timelines don’t matter.” But that’s just a convenient way to avoid dealing with the actual complexity of the logistics, politics, biology, and capital constraints of innovation. Like… just cleaning the data is a huge fucking problem.

I don’t know why this is my current fixation. I woke up feeling very spiritually off-center today. I’ve been feeling kind of exploited and unloved and spiritually abused lately. So this is my fairyland I recede into for respite. Thank you for reading, I love you pretty machine.

☣︎

Technical Footnotes

Starting with a high-demand application like cosmetic breast augmentation provides two main strategic advantages:

1. Scalable and reproducible manufacturing processes

2. A well-defined anatomical context for refining biomechanical characteristics (how soft tissue moves, how it feels, and how it potentially degrades). These seem like purely cosmetic problems, but they are actually fundamental engineering challenges that we absolutely need to figure out for any synthetic soft tissue replacement to work safely, no matter what you're using it for.

Here’s why:

When you push down on natural fat, it squishes and then slowly bounces back, which basically absorbs and spreads out physical forces. If a synthetic version is too hard or too bouncy, it creates concentrated stress points where it meets real tissue. These pressure points can cause chronic inflammation, pain, tissue irritation, implant erosion, pressure ulcers, or simply restrict movement. Achieving a natural feel isn’t just about aesthetics, it’s crucial for how well the body integrates with the material. When an implant feels right, your tissues integrate with it better. Getting the right feel is basically the foundation of biomimetic design across the entire field of regenerative medicine, and is directly applicable to pretty much every synthetic organ and soft tissue replacement we're trying to develop.

Also, it’s important to keep in mind that your cells are not chill. They are really high-maintenance, bitchy, judgmental, demanding, uncompromising, they lose their mind when you ask them to do anything beyond the minimum amount of work required, and have a collective meltdown if they aren’t in their perfect little Goldilocks zone of comfort 24/7. Which we love.

If their environment isn’t just right, they call in the immune system’s SWAT team to clear out the intruder. But if synthetic fat feels like real fat—not too hard, not too springy—your cells are much less likely to freak out and be like, "get this shit out of here.”

So, instead of building thick, ridged scar tissue shell around the implant, which is bad, your body forms a thinner, more flexible one. If the feel is exceptionally natural, your body might even grow tiny blood vessels into the implant, helping it settle in better and last longer. Basically: Good feel = body is friendlier = fewer problems.

Why this matters?

The reason why we’re even bothering with real fake tits in the first place is because synthetic fat is the minimum viable product for synthetic soft tissue. If we can perfect the jiggle physics—and I use that term with all the scientific seriousness it deserves—we can use that knowledge to fix everything else. Hearts, livers, whatever. We’re not just building fake tits. We’re building a roadmap for the future of synthetic soft tissue.

Addendum 10NOV2025 7:34pm PST: Ok bitches here’s how we make it work. Get a pen and take a knee.

Part I: Why Real Fake Tits is the Roadmap for Synthetic-Organ Development

In advancing synthetic-organ engineering, starting with a high-demand cosmetic application (real fake tits, for me specifically) creates a strategic, scientifically grounded roadmap to build the entire field. There are four reasons this is the only approach that works, and I’m going to explain them to you the way I’d explain them to a venture capitalist who’s already reaching for their checkbook because they recognize genius when they see it.​​​​​​​​​​​​​​​​

1. Foundational biomimetic challenge: soft-tissue feel and design

Titties are mostly soft tissue that’s viscoelastic, which means they deform under pressure and slowly return to their original shape. The problem this poses is why bras exist. Gravity is not working with us here. Gravity is, in fact, actively hostile to the structural integrity of breasts, which is why women have spent centuries engineering increasingly complex suspension systems to fight back against the fundamental forces of the universe. And if it’s hard for real tits to retain their shape while being subject to the forces of life, it’s even harder to make fake tits do the same. So this is a big problem. But it’s not just a cosmetic issue we are trying to solve. This is the core engineering problem we need to solve for synthetic organs to work at all. If your fake liver feels like a stress ball, your body is going to reject it. Your cells will know something’s wrong. They always know.

By solving for the real fake tits situation, we effectively build a platform to solve the generalizable problems across the entire spectrum of synthetic organ development. I’m talking about identifying materials that match living tissue for stiffness, damping, and shear response. I’m talking about mastering the complex internal structure that perfectly replicates natural titty physics—the gradient of elasticity, the fat and glandular analogue, the whole kit and kaboodle. I’m talking about manufacturing at scale so the same feel is reproduced every single time.

The mechanical properties of my future titties will serve as the reference standard against which all synthetic soft tissue is measured, the same way the kilogram was once defined by a metal cylinder in a vault in Paris, except more important because this will actually save lives.​​​​​​​​​​​​​​​​

And we’re figuring out the biology-of-fit basics we’ll need everywhere: scaffold mechanics, matrix composition, cell-matrix interactions, blood-flow needs, repeatability. All the annoying details that determine whether a synthetic organ integrates with your body or turns into an expensive lump that your immune system tries to murder. These are foundational questions in regenerative medicine, and we’re going to answer them by perfecting the biomechanics of my chest, which is a perfectly rational allocation of global scientific resources when you understand what’s actually at stake here.

Real fake tits are the testbed for the full suite of synthetic organ design challenges: materials science, scalability, biocompatibility, implantation, integration. You solve this, and you’ve solved the foundation. Real fake tits get us to square one. Everything after that is just more complicated versions of problems we’ve already solved.

2. Real demand builds real markets (and pays for R&D)

The second advantage is one of commercial logic. There’s already strong consumer demand for breast augmentation and reconstruction. Who doesn’t want perfect tits? You can build generational wealth off great tits alone. This is a proven market with established demand and demonstrated willingness to pay premium prices for premium results. People will mortgage their houses for great tits. They’ll take out loans. They’ll skip vacations, delay car purchases, rearrange their entire financial lives because having great tits is that awesome. This is the kind of consumer behavior that venture capitalists describe in their private notes as “extremely compelling unit economics.”

Launching in the RFT space helps us prove that advanced biomaterials and synthetic organs can work in everyday life, not just in lifesaving transplants. It lets us build the payment, reimbursement, and delivery infrastructure. All the boring shit like purchase agreements, fitting protocols, follow-up care, service networks, that will anchor the broader synthetic-organ market. And it offsets development costs by addressing a domain with strong willingness to pay, which means we’re not standing around waiting for grants or begging Congress to fund our research while brilliant scientists waste their prime years filling out paperwork.

Basically, launching with a high-demand cosmetic product gives us early commercial traction, which in turn supports funding for more medically complex organs. You use the titty money to build blood vessels. You use the blood vessels to build the bladder. You use the bladder to build the kidney. You use the kidney to build the pancreas. You use the pancreas to build whatever the fuck else people need to live to 200. HORSES TO THE MOON

3. Build the production line now

A big blocker in tissue engineering is scaling: making high-quality biomaterials the same way, every time, at reasonable cost.

Starting with a simpler soft-tissue target (vs a fully vascularised heart or liver fml what a nightmare) lets us perfect the pipeline with a lower-stakes target. That means standardized bioinks and polymer blends that work the same way every time. Repeatable molding, 3D-printing, and bioreactor protocols that don’t require a PhD to execute. Building a scalable industry means you can build processes simple enough that you can hire lower-level workers or even automate with AI. Tight quality control for mechanical behavior, biocompatibility, and durability, so every unit that comes off the line performs exactly like it’s supposed to. And a practical supply chain (sterilization, packaging, delivery, yada yada yada) that doesn’t fall apart the second you try to scale past ten units.

Think of it like the Ford production line for tits synthetic tissue. Once it exists, we can adapt it to more complex, vascularized, and innervated tissues. Once you know how to manufacture tits at scale without fucking it up, you’ve solved the foundational problem. Everything else is just harder versions of the same thing.

It’s basicallythe same playbook that made SpaceX work. Don’t start with the Mars colony. Start with the thing that pays the bills (launching satellites) and use that revenue to build the rocket that gets us to Mars. Except in this case, the satellites are tits (my tits specifically) and Mars is living to 200 without your organs turning into wet garbage.

4. Regulatory advantage: cosmetic vs transplant-grade oversight

Cosmetic devices (implants, soft-tissue fillers, external prostheses) usually face less regulatory oversight than devices or biologics that replace or support vital organ function. This is because regulatory agencies operate on a simple principle: if it can kill you, we care. If it just makes you hotter, we care less. The FDA doesn’t lose sleep over cosmetic implants the way they do over artificial hearts. Nobody’s writing urgent memos about breast augmentation. There are no emergency task forces. No congressional hearings. No primetime news segments where a concerned anchor furrows their brow and asks if we’re doing enough to protect Americans from getting the tits they specifically asked for and paid thousands of dollars to receive.

So we use the cosmetic pathway as proof of concept. We build up our safety data in an environment where the approval process takes years instead of decades and doesn’t require a clinical trial that needs its own institutional review board to oversee the institutional review board.

We demonstrate that our synthetic tissue integrates properly, maintains its shape over time, and performs exactly as intended. We show years of clinical data proving the material is safe, effective, and reproducible at scale. You’ve got surgeons who know how to implant it. You’ve got supply chains that work. You’ve got manufacturing protocols that produce consistent results. You’ve got insurance companies that have already figured out the reimbursement codes. The entire infrastructure already exists because you built it selling tits to people who were highly motivated to pay for them. And then you’ve got the credibility to move into the life saving stuff, armed with years of clinical data and a track record that proves we know what we’re doing.

The cosmetic path just has less regulatory oversight than life-saving organs. Bureaucracies allocate resources based on perceived risk, and “woman wants giant gazongas” ranks low on the national emergency scale. Success here can de-risk later approvals, build clinical experience with real patients in real-world conditions, and generate safety and performance data we can leverage for higher-stakes organs. You want to convince the FDA that your synthetic liver won’t kill someone? Show them ten thousand women walking around with your synthetic tissue in their chest, living normal lives, not dying, not complaining, posting Instagram stories from the beach.

Bottom line:

Starting with “real fake tits” forces us to solve universal soft-tissue problems, creates a paying market and infrastructure, builds the manufacturing system we’ll need for everything else, and provides a more navigable regulatory path for bringing synthetic organ development to market.

This is how we get to synthetic organs that actually work at scale. The alternative is waiting 30 years for incremental progress while researchers fill out grant applications that get read by committees who schedule meetings to discuss whether they should schedule another meeting. The RFT approach solves real problems with real money behind real demand, and it does it faster than any other pathway currently available. My tits are the foundation upon which we will build the future of human longevity, and history will remember them accordingly.​​​​​​​​​​​​​​​​

Addendum 04JUN2025 2:20pm PST

Asking American tax payers to fund my real fake tits is too a little too communist for my tastes. So instead, I would like to revise the proposal: I am seeking a private investor to commit $230 billion over a five-year period to catalyze this groundbreaking venture. Think of it not as philanthropy, but as legacy.

Serious inquiries may be directed to:

parakeetnebula@gmail.com

☣︎